Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

SLU-PP-332 and Tamoxifen Interaction: Avoid | Peptide Database

Compound Profiles SLU-PP-332 Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathwa

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

SLU-PP-332

Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator

Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.

Tamoxifen

Selective Estrogen Receptor Modulator | PCT & Breast Cancer Treatment

Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take SLU-PP-332 with Tamoxifen?

Combining SLU-PP-332 with Tamoxifen is not recommended. Both SLU-PP-332 and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is SLU-PP-332 and Tamoxifen safe together?

This combination carries significant risk. Both SLU-PP-332 and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between SLU-PP-332 and Tamoxifen?

Both SLU-PP-332 and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 53% confidence and is inferred from pharmacological mechanism analysis.

How should I time SLU-PP-332 and Tamoxifen?

SLU-PP-332 has a half-life of Under investigation (no human PK data) and Tamoxifen has a half-life of ~5-7 days. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Cardarine's most pronounced effect is on aerobic endurance. By upregulating fatty acid oxidation and promoting oxidative muscle fiber characteristics, it substantially increases the duration and intensity at which aerobic exercise can be sustained. Preclinical studies showed up to a 68% increase in running distance in treated mice. Anecdotal reports from human users consistently describe marked improvements in cardiovascular endurance within 1-2 weeks of use. By promoting fatty acid oxidation as the primary metabolic fuel source and reducing lipogenesis, Cardarine accelerates fat loss independently of caloric restriction. The shift toward fat as a fuel substrate means greater caloric expenditure from stored adipose tissue during both exercise and rest. Users report noticeable reductions in body fat, particularly when combined with a structured training program. Cardarine consistently improves blood lipid markers in preclinical and early human data. It increases HDL cholesterol, decreases LDL cholesterol, and reduces triglycerides. This property makes it of particular interest as a co-administration agent during SARM or anabolic steroid cycles, which typically worsen lipid profiles. Cardarine was originally developed for the treatment of dyslipidemia and metabolic syndrome. Early Phase I/II human data demonstrated favorable shifts in lipid profiles at low doses. Development was halted before efficacy trials could be completed due to the carcinogenicity findings in rodent models. Preclinical data supported Cardarine's potential for treating obesity and metabolic syndrome through enhanced fat oxidation and improved insulin sensitivity. These indications were never pursued to clinical completion due to safety concerns.

Source: peptide-db.com ↗

Research Indications

ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss. ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss. Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%). 91% achieved near-normal blood sugar levels versus 42% with placebo. ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%. Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Superdrol is administered exclusively by the oral route as a 17-alpha-alkylated steroid. It was historically available in capsule or tablet form, typically dosed at 10 mg per unit. Due to its extreme hepatotoxicity, cycle lengths must be kept as short as possible and liver support supplementation is mandatory rather than optional. There is no injectable formulation in common use. Performance - Conservative / First-Time Users 10 mg/day Once daily or split into 2 doses Oral Performance - Standard 20 mg/day Split into 2 doses (morning and evening)

Source: peptide-db.com ↗
Side effects

Common Side Effects

HDL cholesterol suppression (dose-dependent, most significant lipid effect) LDL cholesterol elevation Mild hepatic stress (elevated liver enzymes ALT/AST) Suppression of endogenous testosterone production Mild headaches Nausea or gastrointestinal discomfort Changes in libido (increase or decrease depending on hormonal context) Oily skin and mild acne

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides